NCT03995121Active, not recruiting
SV2 PET Imaging With [11C]APP311
Synaptic Density in Psychiatric Disorders Using SV2A Receptor PET Imaging With [11C]APP311
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
The aim of this study is to evaluate a new SV2A tracer, \[11C\]APP311, in healthy aging and neuropsychiatric disorders including psychotic disorders and cannabis use disorders.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 19 Jun 2019
- Start date
- 1 Dec 2017
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Yale University
- Diseases
- Schizophrenia
- NCT number
- NCT03995121
What you commit to
- Study type: Observational
- Planned participants: 250
- From 1 Dec 2017 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- MRI metal exclusions and claustrophobia.
- Education completed is less than 12 years
Who the study is looking for
- Willing and able to give voluntary written informed consent
- Male and Female subjects, age 18 to 65 years, inclusive
Age in the registry: 18 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Conneticut Mental Health Center Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.